{
  "trial_id": "NCT00314366",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "consented to the study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "extensive baseline testing will be completed at St. Luke's Episcopal Hospital in Houston, Texas",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "bone marrow harvested and later injected",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "NOGA mapping is performed",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "processed cells or placebo are injected under electromechanical guidance into the affected areas of the left ventricle",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "follow-up at weeks 1 and 4, and months 3 and 6, and at one year unless there is a crossover",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "quality of life and NOGA mapping are done at the time of injection, as well as at 6 months",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "This is a phase I, double blind trial to evaluate the use of Aldehyde Dehydrogenase-Bright (ALDHbr) in ischemic cardiomyopathy patients",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "transendocardial injections of autologous bone marrow cells in patients with end-stage ischemic heart disease is safe, can provide neovascularization, and can improve perfusion and myocardial contractility",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "The primary object of this study is to assess the safety of the ALDHbr cell injections",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "A maximum of 60 patients will be enrolled in the study",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Canadian cardiovascular (CV) Class II-IV angina and/or congestive heart failure (CHF) symptoms",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Ejection fraction less than or equal to 45%",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Age less than 18 or greater than 70",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Atrial fibrillation",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Severe valve disease",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "History of cancer in last 5 years",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "HIV positive; hepatitis B or C positive.",
      "label": "triggers",
      "evidence": "quote"
    }
  ],
  "notes": "The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He has mild symptoms and no signs of dementia.",
  "_meta": {
    "topic_id": "75",
    "trial_id": "NCT00314366",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}